N/A N=40 Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision
Breast-Conserving Surgery
Primary: Volume Restoration — 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=243 A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
Depressive Disorder, Major
Primary: Change From Baseline in MADRS Total Score at Week 6 — -12.0; -7.8; -11.9; -12.3 units on a scale — p=0.2645
N/A N=50,798 Prevent TB: Choice Architecture for TPT Delivery
HIV/AIDS · Tuberculosis
Primary: Percentage of Patients Newly Starting ART Also Initiating TPT Within 90 Days of ART Initiation — 70.1; 71.5 Percentage of participants
Phase 3 N=80 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
Phase 3 N=301 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Hypercholesterolemia
Primary: Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56 — -64.6; -6.3; -27.8; -36.5 Percent Change — p=<0.001
Phase 1 N=6 A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte ([14C]-BI 425809 After iv Administration as Well as for BI 425809 After Oral Administration) Over the Time…
Phase 1 N=28 A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs). — 1; 1; 1; 2 Participants
Phase 3 N=31 A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8 — 99.8 Percentage of ZLP-AI…
Phase 2 N=530 Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction
ST Elevation Myocardial Infarction · Inflammatory Response · Myocardial Reperfusion Injury
Primary: Final Infarct Size — 5; 6 % of LV
N/A N=50 The Energize! Study for Adults With Knee Replacement
Knee Arthroplasty
Primary: Minutes of Moderate to Vigorous Intensity Physical Activity — 70.89; -7.71 minutes/week
N/A N=60 Pharmacokinetic and Subjective Effects of Heated Tobacco Products
Tobacco Use
Primary: Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment — 6.426; 7.953; 8.288; 7.993 ng/mL
N/A N=33 Time Restricted Eating for Metabolic and Psychological Optimization
Mild Cognitive Impairment · Obesity
Primary: Change in Memory Composite Rank — 6.22 rank — p=<0.001
N/A N=479 Text Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids
Opioid Misuse
Primary: Percentage of Participants Who Securely Stored Their Opioid Medication During Treatment — 48; 29; 140; 181 Participants — p=0.003
Phase 2 N=190 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Primary: Overall Survival (OS) — 8.08; 4.76; 6.67 months — p=0.7689
Phase 2 N=176 Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Plantar Fibromatosis
Primary: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score — -9.844; -8.417 score on a scale — p=0.274